Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
FDA appears ready to rethink antibiotic development
An advisory panel's vote last week is among the signals that the FDA may be ready to reconsider the requirements for the clinical trials of antibiotics. As multidrug-resistant bacteria strains have become more common, new antibiotic approvals have decreased.
Or we can send an email on your behalf